Lilly

Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…

Kyle LaHucik · 2026-08-27

As its world-leading GLP-1 earns more than any other medicine — and its market cap eclipses all other healthcare companies — Eli Lilly has decided to stop disclosing its Phase 1 pipeline. Lilly

Source: Endpoints News